Tags

Type your tag names separated by a space and hit enter

Methylenetetrahydrofolate reductase polymorphism determines the plasma homocysteine-lowering effect of large-dose folic acid supplementation in patients with cardiovascular disease.
Nutrition 2004 Nov-Dec; 20(11-12):974-8N

Abstract

OBJECTIVE

The polymorphism of the gene encoding methylenetetrahydrofolate reductase (MTHFR) and folic acid nutritional status play important roles in atherosclerosis. The present study investigated the total homocysteine-lowering effect of folic acid in response to the MTHFR genotype in patients who have cardiovascular disease.

METHODS

Twenty-three patients who had cardiovascular disease (ages 44 to 88 y) were supplemented with 5 mg of folic acid/d for 8 wk. Blood samples were collected before and after supplementation for the measurement of folic acid. The presence of the 677C-->T mutation was assessed by polymerase chain reaction followed by restriction enzyme analysis.

RESULTS

After the 8 wk of folic acid supplementation, plasma total homocysteine decreased 40% in patients who had the TT genotype, 23% in those who had the CT genotype, 10% in those who had the CC genotype, and 27% in carriers of the T allele. The plasma total homocysteine-lowering effect of folic acid was significant only in patients who had the CT genotype and in carriers of the T allele.

CONCLUSIONS

The MTHFR polymorphism may be involved in the total homocysteine-lowering effect of folic acid in patients who have cardiovascular disease.

Authors+Show Affiliations

Department of Neurology and Neuroscience, Changhua Christian Hospital, Changhua, Taiwan.No affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

15561486

Citation

Liu, Chin-San, et al. "Methylenetetrahydrofolate Reductase Polymorphism Determines the Plasma Homocysteine-lowering Effect of Large-dose Folic Acid Supplementation in Patients With Cardiovascular Disease." Nutrition (Burbank, Los Angeles County, Calif.), vol. 20, no. 11-12, 2004, pp. 974-8.
Liu CS, Chiang HC, Chen HW. Methylenetetrahydrofolate reductase polymorphism determines the plasma homocysteine-lowering effect of large-dose folic acid supplementation in patients with cardiovascular disease. Nutrition. 2004;20(11-12):974-8.
Liu, C. S., Chiang, H. C., & Chen, H. W. (2004). Methylenetetrahydrofolate reductase polymorphism determines the plasma homocysteine-lowering effect of large-dose folic acid supplementation in patients with cardiovascular disease. Nutrition (Burbank, Los Angeles County, Calif.), 20(11-12), pp. 974-8.
Liu CS, Chiang HC, Chen HW. Methylenetetrahydrofolate Reductase Polymorphism Determines the Plasma Homocysteine-lowering Effect of Large-dose Folic Acid Supplementation in Patients With Cardiovascular Disease. Nutrition. 2004;20(11-12):974-8. PubMed PMID: 15561486.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Methylenetetrahydrofolate reductase polymorphism determines the plasma homocysteine-lowering effect of large-dose folic acid supplementation in patients with cardiovascular disease. AU - Liu,Chin-San, AU - Chiang,Hui-Chin, AU - Chen,Haw-Wen, PY - 2003/10/06/received PY - 2004/04/12/accepted PY - 2004/11/25/pubmed PY - 2005/4/9/medline PY - 2004/11/25/entrez SP - 974 EP - 8 JF - Nutrition (Burbank, Los Angeles County, Calif.) JO - Nutrition VL - 20 IS - 11-12 N2 - OBJECTIVE: The polymorphism of the gene encoding methylenetetrahydrofolate reductase (MTHFR) and folic acid nutritional status play important roles in atherosclerosis. The present study investigated the total homocysteine-lowering effect of folic acid in response to the MTHFR genotype in patients who have cardiovascular disease. METHODS: Twenty-three patients who had cardiovascular disease (ages 44 to 88 y) were supplemented with 5 mg of folic acid/d for 8 wk. Blood samples were collected before and after supplementation for the measurement of folic acid. The presence of the 677C-->T mutation was assessed by polymerase chain reaction followed by restriction enzyme analysis. RESULTS: After the 8 wk of folic acid supplementation, plasma total homocysteine decreased 40% in patients who had the TT genotype, 23% in those who had the CT genotype, 10% in those who had the CC genotype, and 27% in carriers of the T allele. The plasma total homocysteine-lowering effect of folic acid was significant only in patients who had the CT genotype and in carriers of the T allele. CONCLUSIONS: The MTHFR polymorphism may be involved in the total homocysteine-lowering effect of folic acid in patients who have cardiovascular disease. SN - 0899-9007 UR - https://www.unboundmedicine.com/medline/citation/15561486/Methylenetetrahydrofolate_reductase_polymorphism_determines_the_plasma_homocysteine_lowering_effect_of_large_dose_folic_acid_supplementation_in_patients_with_cardiovascular_disease_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0899-9007(04)00187-X DB - PRIME DP - Unbound Medicine ER -